Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Helena Rebelo de ANDRADE"'
Autor:
João Trigueiro-Louro, Vanessa Correia, Inês Figueiredo-Nunes, Marta Gíria, Helena Rebelo-de-Andrade
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 18, Iss , Pp 2117-2131 (2020)
There are no approved target therapeutics against SARS-CoV-2 or other beta-CoVs. The beta-CoV Spike protein is a promising target considering the critical role in viral infection and pathogenesis and its surface exposed features. We performed a struc
Externí odkaz:
https://doaj.org/article/a92e138139094ccea9f09fa631c8d277
Autor:
Francisco Faísca, Vanessa Correia, Željko Petrovski, Luís C. Branco, Helena Rebelo-de-Andrade, Miguel M. Santos
Publikováno v:
Pharmaceutics, Vol 14, Iss 4, p 877 (2022)
The development of effective antiviral drugs against SARS-CoV-2 is urgently needed and a global health priority. In light of the initial data regarding the repurposing of hydroxychloroquine (HCQ) to tackle this coronavirus, herein we present a quanti
Externí odkaz:
https://doaj.org/article/b8e4f34bf4c34fe6abb3fa56e62e4237
Publikováno v:
Ler História, Vol 73, Pp 67-92 (2018)
The pneumonic influenza pandemic was, on a world scale, the deadliest of the entire 20th century. Between spring 1918 and April 1919, it raged in Portugal in three successive waves, with an irregular and unusual virulence, which were marked by an int
Externí odkaz:
https://doaj.org/article/f6725779c0224b98846ffaa6e95f08b4
Autor:
Susana David, Guillermo Dorado, Elsa L. Duarte, Stephanie David-Bosne, João Trigueiro-Louro, Helena Rebelo-de-Andrade
Publikováno v:
Immunogenetics. 74:381-407
COVID-19 is a new complex multisystem disease caused by the novel coronavirus SARS-CoV-2. In slightly over 2 years, it infected nearly 500 million and killed 6 million human beings worldwide, causing an unprecedented coronavirus pandemic. Currently,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48d7381ad1be9707eb890a0d4aba1c5b
https://doi.org/10.1007/s00251-022-01261-w
https://doi.org/10.1007/s00251-022-01261-w
Autor:
Rui M. M. Brito, Filipe Almeida, João Trigueiro-Louro, Vanessa Correia, Luís A. Santos, Helena Rebelo-de-Andrade
Publikováno v:
Virology. 565:106-116
Influenza NS1 is a promising anti-influenza target, considering its conserved and druggable structure, and key function in influenza replication and pathogenesis. Notwithstanding, target identification and validation, strengthened by experimental dat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::594b65531f891fc59c3300f41154dc4a
https://doi.org/10.1016/j.virol.2021.11.001
https://doi.org/10.1016/j.virol.2021.11.001
Influenza and COVID-19 are infectious respiratory diseases that represent a major concern to public health with social and economic impact worldwide, for which the available therapeutic options are not satisfactory. The RdRp has a central role in vir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4646184103c55842d5c93a6c410da942
https://hdl.handle.net/10400.18/8587
https://hdl.handle.net/10400.18/8587
PB1 influenza virus retain traces of interspecies transmission and adaptation. Previous phylogenetic analyses highlighted mutations L298I, R386K and I517V in PB1 to have putatively ameliorated the A(H1N1)pdm09 adaptation to the human host. This study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d684c38080310174e015e0fb646b889
https://hdl.handle.net/10400.18/8567
https://hdl.handle.net/10400.18/8567
Autor:
Helena Rebelo-de-Andrade, Marta Gíria, João M. Trigueiro-Louro, Vanessa Correia, Inês Figueiredo-Nunes
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 18, Iss, Pp 2117-2131 (2020)
Computational and Structural Biotechnology Journal
Computational and Structural Biotechnology Journal
Graphical abstract
Highlights • Human SARSr-CoV Spike protein is highly conserved in both S1 and S2 subunits. • The S1-RBD, -SD1; S2-CR, -HR1 and -CH are the most promising druggable S regions. • 28 main consensus druggable pockets were fo
Highlights • Human SARSr-CoV Spike protein is highly conserved in both S1 and S2 subunits. • The S1-RBD, -SD1; S2-CR, -HR1 and -CH are the most promising druggable S regions. • 28 main consensus druggable pockets were fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c63598730c179325ddc5c9d3b95a8608
http://www.sciencedirect.com/science/article/pii/S2001037020303494
http://www.sciencedirect.com/science/article/pii/S2001037020303494
Autor:
Jacques R. Kremer, Kevin E. Brown, Li Jin, Sabine Santibanez, Sergey V. Shulga, Yair Aboudy, Irina V. Demchyshyna, Sultana Djemileva, Juan E. Echevarria, David F. Featherstone, Mirsada Hukic, Kari Johansen, Bogumila Litwinska, Elena Lopareva, Emilia Lupulescu, Andreas Mentis, Zefira Mihneva, Maria M. Mosquera, Mark Muscat, M.A. Naumova, Jasminka Nedeljkovic, Ljubov S. Nekrasova, Fabio Magurano, Claudia Fortuna, Helena Rebelo de Andrade, Jean-Luc Richard, Alma Robo, Paul A. Rota, Elena O. Samoilovich, Inna Sarv, Galina V. Semeiko, Nazim Shugayev, Elmira S. Utegenova, Rob van Binnendijk, Lasse Vinner, Diane Waku-Kouomou, T. Fabian Wild, David W.G. Brown, Annette Mankertz, Claude P. Muller, Mick N. Mulders
Publikováno v:
Emerging Infectious Diseases, Vol 14, Iss 1, Pp 107-114 (2008)
During 2005–2006, nine measles virus (MV) genotypes were identified throughout the World Health Organization European Region. All major epidemics were associated with genotypes D4, D6, and B3. Other genotypes (B2, D5, D8, D9, G2, and H1) were only
Externí odkaz:
https://doaj.org/article/d72d597f21f8434e8dee4a71c90640aa
Publikováno v:
Virus Research. 315:198795
Vaccination prevents and reduces the severity of influenza virus infections. Continuous evolution of influenza hemagglutinin (HA) and neuraminidase (NA) supports the virus to evade pre-existing immunity, which demands vaccines to be reformulated ever
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16308c8f15dfdfe8c93cb8ccfe3e2c97
https://doi.org/10.1016/j.virusres.2022.198795
https://doi.org/10.1016/j.virusres.2022.198795